

C1
conclude

83 (amended). The composition according to claim [82] 101 wherein the [isolated dendritic cell precursors ~~have~~ been pulsed with an antigen *in vitro*] dendritic cell precursors are derived from the method according to claim 82.

C2

96 (amended). A pharmaceutical composition comprising a therapeutic amount of an enriched population of human dendritic cells and a pharmaceutically acceptable carrier.

Please add the additional claim:

~~Sub E~~
C3
Sub E6

-- 101. An *in vitro* composition comprising an enriched population of processed antigen presenting dendritic cell precursors, wherein said dendritic cell precursors present processed antigen derived from said dendritic cell precursors contacted *in vitro*, in the presence of GM-CSF, with antigen for sufficient time for said dendritic cell precursors to process and present said processed antigen.--

REMARKS

Claims 82-100 are pending in the application. Claims 86-88, 90-93, 98, and 100 stand withdrawn as relating to a non-elected group. Claims 82-85, 89, 94-97 and 99 stand rejected.

Claims 82 and 83 have been amended and claim 101 has been added. Neither the amendments nor additional claim adds new matter.

Claim 82 has been amended to recite that the composition is one which is *in vitro* and comprises an enriched population of dendritic cell precursors in the presence of GM-CSF. Support for these amendments is present in the specification which discloses methods of obtaining cultures of proliferating dendritic cell precursors. See, for